Identifying proteomic risk factors for overall, aggressive, and early onset prostate cancer using Mendelian Randomisation and tumour spatial transcriptomics
Open Access
- 14 June 2024
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 105, 105168
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Medical Research Council (MC_UU_00011/6)
- Medical Research Council (MC_UU_00011/1)
- Medical Research Council (MC_UU_00011/4)
- Medical Research Council (MC_UU_00011/3)
- National Institute for Health and Care Research (NIHR202411)
- Centre International de Recherche sur le Cancer
- University Hospitals Bristol NHS Foundation Trust
- National Institutes of Health
- University of Bristol
- NIHR Bristol Biomedical Research Centre
- John Black Charitable Foundation
- UK Research and Innovation (10063259)
- World Health Organization
- Cancer Research UK (C8221/A29017)
- Cancer Research UK (C18281/A29019)
- Cancer Research UK (C8221/A30904)
- Cancer Research UK (C16077/A29186)
This publication has 70 references indexed in Scilit:
- ATF6α promotes prostate cancer progression by enhancing PLA2G4A‐mediated arachidonic acid metabolism and protecting tumor cells against ferroptosisThe Prostate, 2022
- Roles of matrix metalloproteinase-7 (MMP-7) in cancerClinical Biochemistry, 2021
- Early‐onset prostate cancer is associated with increased risks of disease progression and cancer‐specific mortalityThe Prostate, 2020
- The Novel Transcription Factor CREB3L4 Contributes to the Progression of Human Breast CarcinomaJournal of Mammary Gland Biology and Neoplasia, 2020
- PPP2R5A: A multirole protein phosphatase subunit in regulating cancer developmentCancer Letters, 2018
- The potential value of microseminoprotein‐β as a prostate cancer biomarker and therapeutic targetThe Prostate, 2009
- The Role of Plasminogen-Plasmin System in Cancer2009
- Contribution of the 37-kDa laminin receptor precursor in the anti-metastatic PSP94-derived peptide PCK3145 cell surface bindingBiochemical and Biophysical Research Communications, 2006
- A prostate secretory protein94‐derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: Implication in tumor angiogenesisInternational Journal of Cancer, 2005
- A PSP94-derived Peptide PCK3145 inhibits MMP-9 Secretion and Triggers CD44 Cell Surface Shedding: Implication in Tumor MetastasisClinical & Experimental Metastasis, 2005